Navigation Links
ChanTest Introduces the CardioChannelGram™ and SaVety Assessment
Date:4/16/2013

Cleveland, OH (PRWEB) April 16, 2013

Determining the drug-induced inhibition of the cardiac hERG potassium channel is recommended by both the International Conference on Harmonization (ICH) and the US Food and Drug Administration (FDA) in order to predict delayed cardiac repolarization (DR) and cardiac risk. However, extending this determination to actually identifying drugs that may cause TdP, a serious polymorphic ventricular tachycardia, has been challenging.

In response to this need, ChanTest has introduced the CardioChannelGram™ - cardiac ion channel profiling plus logistic regression models that predict DR and TdP risk. Predictivity is significantly better when quantitative drug effects on Cav1.2 and Nav1.5 ion channels, in addition to hERG, are measured. Cardiac risk can now be characterized earlier in development than ever before using automated patch clamp platforms.

“ChanTest is pleased to be responding to the industry's needs by introducing this new line of testing to the drug discovery community,” said Arthur "Buzz" Brown, Ph.D., M.D., CEO, President and founder. “Our new CardioChannelGram™ and SaVety Assessment will provide greater insight into potential cardiac risk, allowing more effective decision-making in early preclinical development.”

Click here to learn more about the ChanTest CardioChannelGram™ and SaVety Assessment.

FURTHER INFORMATION
ChanTest
14656 New Parkway
Cleveland, Ohio 44128
1-877-828-1777 Toll Free
1-216-332-1665 Tel
1-216-332-1706 Fax
info(at)chantest(dot)com

Contact for Media Inquiries:

Chris Mathes, Ph.D., M.B.A.
Chief Commercial Officer
cmathes(at)chantest(dot)com
http://www.chantest.com

About ChanTest® – The Ion Channel Expert

ChanTest’s mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the CRO has tested compounds for more than 500 global pharmaceutical and biotechnology companies, and partners with them to speed the drug development process for the release of better, safer drugs.

ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines, and nonclinical cardiac risk assessment service portfolio, is the most comprehensive commercially available today.

Because of ChanTest’s seminal role in the nonclinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the “most trusted and most used fee-for-service provider” for ion channel screening in an independent survey for the past several years. ChanTest is based in Cleveland, Ohio.

Visit http://www.chantest.com to learn more about what we do.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10634495.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. ChanTest Announces Their Second User Meeting: Partnerships in Drug Discovery
2. ChanTest Announces a Complimentary Webinar on the Use of the xCELLigence System
3. Diagenode Introduces Innovative Bioruptor® Pico for Micro-Volume Chromatin and DNA Shearing
4. Texas Fertility Center Introduces Oncofertility Education Program for Physicians and Patients
5. Finesse Solutions Introduces SmartParts for Intelligent Universal Controllers
6. Cearna Introduces Product Designed to Reduce Patient’s Recovery Time From Facial Plastic Surgery
7. Rigaku Introduces New Instruments at Pittcon 2013
8. GIN Introduces Advanced Robotics and Dispensing Technology at BVS La Jolla Biotech Day
9. FMC BioPolymer Introduces Its New Portfolio of Nature-Based Nutritional Solutions
10. Percival Scientific, Inc. Introduces an Affordable LED Lighting System for the Research Industry
11. Palomar Medical Center in San Diego County Introduces New Wrist-Worn Wireless Patient Vital Signs Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, ... microbial test has received AOAC Research Institute approval 061601. , “This is another ... year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel ...
Breaking Biology Technology:
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
(Date:3/21/2016)... Unique technology combines v ... security   Xura, Inc. ... digital communications services, today announced it is working alongside ... customers, particularly those in the Financial Services Sector, the ... within a mobile app, alongside, and in combination with, ...
Breaking Biology News(10 mins):